Back to search

PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC

NCT04974281

EARLY_PHASE1INTERVENTIONAL
Fudan University
50 participants
Started 2021-01-01 · Completed 2022-12-31
Status: Unknown (as of 12-23-2025)

Conditions

Hepatocellular Carcinoma

Linked Papers (from SciSciNet-V2)

Total Papers5
Background
2
Result
0
Derived
0
Unknown
3

Total Citations Per Year

Brief Summary

The purpose of this study is to assess the difference of safety and efficacy about PD-1 Antibody and Lenvatinib Plus transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma with BCLC B/C.